{"id":"NCT01421069","sponsor":"Pfizer","briefTitle":"Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis","officialTitle":"AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1-3338-WW(B1801014)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-10","primaryCompletion":"2021-02-04","completion":"2021-02-04","firstPosted":"2011-08-22","resultsPosted":"2022-11-14","lastUpdate":"2022-11-14"},"enrollment":109,"design":{"allocation":"NA","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Idiopahtic Arthritis"],"interventions":[{"type":"DRUG","name":"etanercept","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) \\[extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic arthritis (PsA)\\] who have completed approximately 96 weeks of participation in study 0881A1-3338 (B1801014). The study contains an active treatment period, withdrawal/re-treatment period and a observational period (non-treatment).","primaryOutcome":{"measure":"Number of Participants With Malignancy: All Periods of Parent and Extension Study","timeFrame":"First dose of study medication in parent study up to 96 months in the extension study, for a maximum duration of 118 months (22 months of parent study and 96 months of extension study)","effectByArm":[{"arm":"Etanercept","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["Australia","Belgium","Colombia","Czechia","France","Germany","Hungary","Italy","Latvia","Lithuania","Mexico","Netherlands","Norway","Poland","Russia","Serbia","Slovakia","Slovenia","Spain"]},"refs":{"pmids":["37140539","31122296"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801023&StudyName=Extension%20Study%20Evaluating%20Etanercept%20in%203%20Subtypes%20of%20Childhood%20Arthritis%0A"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":109},"commonTop":["Upper respiratory tract infection","Pharyngitis","Bronchitis","Arthralgia","Gastroenteritis"]}}